2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, (CAR)-T Cell Therapies, Women’s Health, Adverse Events, Biological Processes, Pathogenesis, Genomics, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Bleeding Disorders, Thrombocytopenias, Thrombotic Disorders, VWD, Genetic Disorders, Immunology, Autoimmune Disorders, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Non-Hodgkin Lymphoma, Research, APL, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Elderly, Pregnant, Animal Model
PAPER

1292 Off-label use of efanesoctocog alfa for achieving hemostasis in acquired von Willebrand syndrome: A two-case series and literature review

Christina Nelson, MD, Shannon Goodall, MD2, Fouad Nahhat, MD3, Laura El Halabi, MD4, Maissaa Janbain, MD5
1 Tulane University School of Medicine, New Orleans, Louisiana, United States
2 Tulane University School of Medicine, New Orleans, Louisiana, United States
3 Tulane University School of Medicine, New Orleans, Louisiana, United States
4 Tulane University School of Medicine, New Orleans, Louisiana, United States
5 Tulane University School of Medicine, New Orleans, Louisiana, United States

Background 

Acquired von Willebrand syndrome (AvWS) is a rare bleeding disorder involving increased clearance of circulating von Willebrand factor (vWF) due to lymphoproliferative, myeloproliferative, or cardiovascular diseases. In addition to treating the underlying disease, treatment involves hemostatic therapies such as desmopressin (DDAVP), factor VIII (FVIII)/vWF concentrates, and intravenous immunoglobulin (IVIG). However, limitations of these therapies include transient response to DDAVP, rapid clearance of vWF products, and delayed onset of IVIG effect. Efanesoctocog alfa is a high-sustained recombinant FVIII replacement therapy with known efficacy in inherited hemophilia A. According to current literature, the off-label use of efanesoctocog alfa to achieve hemostasis has been observed in congenital types 2N and 3 von Willebrand disease (vWD). However, its role in AvWS remains unknown. We present two cases of efanesoctocog alfa in AvWS in context of the current literature.  

Case 1 
An 82 year old man diagnosed around age 59 with presumed inherited severe vWD (characterized by absent multimers, baseline vWF antigen <10%, vWF activity <10%, and FVIII activity 9%) experienced refractory bleeding from femoral access site requiring 12 units of blood over 2 weeks. Despite FVIII/vWF infusions, his vWF antigen, vWF activity, and FVIII activity remained low, suggestive of accelerated clearance of vWF. With concern for ongoing bleeding, efanesoctocog alfa 50 units/kg was initiated as rescue hemostatic therapy. After efanesoctocog alfa infusion, FVIII activity increased to 77% at 3 hours and maintained 70% at 24 hours. Subsequent workup identified IgG kappa monoclonal gammopathy of undetermined significance (MGUS), which in conjunction with his history was consistent with AvWS. IVIG therapy was initiated, followed by improvement in vWF activity, vWF antigen, and FVIII activity, increasing from <12.5%, 8.9%, and 31.7%, respectively, to 32%, 52.4%, and 69%, respectively. During the early response period of IVIG, the patient had melena with hemoglobin decline from 10.3 to 7.5 g/dL over 48 hours. Efanesoctocog alfa administration was repeated as adjunctive hemostatic therapy, with resolution of bleeding and improvement in FVIII activity to 136%  

Case 2 
A 70 year old man with AvWS secondary to smoldering multiple myeloma (SMM) developed an NSTEMI after initiating IVIG therapy. Prior labs exhibited significant AvWS with vWF GpIbM activity <5%, vWF antigen 8%, and FVIII activity 8%. He required continuous infusion of FVIII/VWF concentrate during angiography and percutaneous coronary intervention. Due to need for month-long dual-antiplatelet therapy (DAPT) and ongoing bleeding risk, he was started on weekly efanesoctocog alfa 50 units/kg for 4 total doses, with subsequent FVIII activity trough level of 11.7% after completion of therapy.  

Discussion  
Current literature on off-label efanesoctocog alfa use in vWD is limited to one case study for periprocedural hemostasis in inherited homozygous type 2N vWD and a phase 1 open label study assessing pharmacokinetic impact and safety in 6 adults with either type 2N or type 3 vWD. The former report demonstrated maintenance of target level FVIII activity with efanesoctocog alfa while avoiding supraphysiologic vWF in a patient with high thrombotic risk with coronary stent. The latter study exhibited improvement in FVIII activity after a single dose of efanesoctocog alfa for perioperative hemostasis in type 2N VWD while avoiding supraphysiologic VWF levels. While both studies each demonstrate sustained FVIII activity to achieve effective hemostasis in inherited vWD, the role of efanesoctocog alfa in AvWS has not yet been reported. In our two cases of AvWS related to plasma dyscrasias, efanesoctocog alfa was observed to achieve hemostasis as rescue therapy in active bleeding and effective prophylaxis during DAPT without excessive vWF exposure, respectively, via sustained FVIII activity. The benefit of efanesoctocog alfa in this context is likely from its incorporation of the vWF D’D3 domain to stabilize recombinant FVIII independent of endogenous vWF. These observations suggest efanesoctocog alfa as a potential clinical alternative for AvWS treatment limited by rapid clearance of vWF-containing products and IVIG contraindications or delayed effect. Although based on only two cases, these observations support efanesoctocog alfa as a novel adjunctive therapy in AvWS.

Christina Nelson, MD: No relevant conflicts of interest to declare.